Immunotherapy aims to mop up lingering HPV after throat cancer treatment
NCT ID NCT05363709
First seen Jan 17, 2026 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This study tests whether the immunotherapy drug BALSTILIMAB can clear HPV virus from the blood of 20 people who have been treated for HPV-positive oropharyngeal cancer but still have signs of the virus. The goal is to see if clearing the virus leads to better long-term cancer control. Participants will receive the drug and be monitored for viral clearance and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.